PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 152 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2018. The put-call ratio across all filers is 1.02 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $48,000 | -26.2% | 12,732 | 0.0% | 0.00% | – |
| Q4 2019 | $65,000 | – | 12,732 | +50828.0% | 0.00% | – |
| Q3 2019 | $0 | -100.0% | 25 | -99.9% | 0.00% | -100.0% |
| Q2 2019 | $137,000 | +33.0% | 22,172 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $103,000 | +25.6% | 22,172 | +13.9% | 0.00% | 0.0% |
| Q4 2018 | $82,000 | -96.2% | 19,472 | -94.4% | 0.00% | -94.1% |
| Q3 2018 | $2,183,000 | +24.2% | 348,203 | +59.3% | 0.02% | +13.3% |
| Q2 2018 | $1,758,000 | +7.8% | 218,623 | 0.0% | 0.02% | 0.0% |
| Q1 2018 | $1,631,000 | +25.9% | 218,623 | +0.5% | 0.02% | +36.4% |
| Q4 2017 | $1,295,000 | -25.1% | 217,572 | -7.3% | 0.01% | -31.2% |
| Q3 2017 | $1,728,000 | +19.5% | 234,777 | +10.2% | 0.02% | +14.3% |
| Q2 2017 | $1,446,000 | +31.0% | 212,986 | +82.2% | 0.01% | +40.0% |
| Q1 2017 | $1,104,000 | – | 116,904 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARDSLEY ADVISORY PARTNERS LP | 1,255,000 | $5,823,000 | 1.12% |
| Phocas Financial Corp. | 1,146,292 | $5,319,000 | 0.54% |
| Worth Venture Partners, LLC | 138,357 | $641,000 | 0.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,293,179 | $10,640,000 | 0.34% |
| Monashee Investment Management LLC | 240,000 | $1,114,000 | 0.26% |
| BKS ADVISORS, LLC | 118,587 | $550,000 | 0.22% |
| PINNACLE ASSOCIATES LTD | 1,418,391 | $6,581,000 | 0.15% |
| FARALLON CAPITAL MANAGEMENT LLC | 4,200,820 | $19,492,000 | 0.15% |
| Fosun International Ltd | 472,580 | $2,174,000 | 0.14% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $18,318,000 | 0.13% |